Strategic Opportunity PlexiClot targets a large $1.9B brain and spinal surgery hemostasis market with a novel mechanism that could reduce reoperation rates and hospital costs, presenting a compelling value proposition for neurosurgery centers and procurement teams.

Regulatory Milestone FDA-specific brain surgery approval planned as a first, with high interest from surgeons; strong potential for strategic partnerships or co-development deals during the regulatory pathway and pre-approval commercialization.

Clinical Advantage 8 issued patents protecting composition, manufacture, and mechanism of action create defensible IP, enabling exclusive or preferred supplier status with neurosurgical departments and hospital networks.

Funding & Network Small, well-connected team with experienced leadership and a cadre of physician investors, offering inbound advocacy and potential pilot programs with academic medical centers and hospital systems.

Expansion Readiness Planning to scale production post-animal trials signals readiness for supplier qualification, manufacturing partnerships, and contract manufacturing opportunities to support large-scale rollout across hospitals and distributors.